The human genome encodes more than 700 G-protein-coupled receptors (GPCRs), many of which are involved in hormone secretion. To date, more than 100 gain-offunction (activating) mutations in at least ten genes for GPCRs, in addition to several loss-of-function mutations, have been implicated in human endocrine disorders.
| INTRODUCTION
G-protein-coupled receptors (GPCRs) are integral membrane proteins characterized by 7 transmembrane domains. [1] [2] [3] The human genome encodes more than 700 GPCRs. 1, 2 GPCRs serve as sensors for internal stimuli, such as hormones, ions and chemokines, as well as for external stimuli such as light, odour and taste. 2 GPCRs play particularly important roles in the endocrine system. [1] [2] [3] [4] Genetic defects in GPCRs have been implicated in various human disorders, including endocrine diseases. 1, 3 Most pathogenic GPCR mutations encode loss-of-function mutant proteins; however, some of these mutations generate mutant receptors with excessive signal transduction activity. Several pathogenic gain-of-function (activating) mutations in GPCR genes have been identified in germline and somatic cells. 1, 3 Such activating mutations can underlie distinctive endocrine syndromes, as well as relatively common hormonal abnormalities.
Recent studies have suggested that gain-of-function mutations in
GPCR genes include not only specific missense substitutions, but also frameshift mutations, intragenic deletions and copy-number gains.
Pathogenic GPCR mutants likely underlie endocrine disorders through various mechanisms including constitutive activation. This review article aims to introduce new aspects regarding gain-of-function mutations in GPCR genes that lead to human endocrine disorders.
| PROTEIN STRUCTURE AND BIOLOGICAL FUNCTIONS OF GPCRS
All GPCRs share characteristic protein structures consisting of an amino (N)-terminal extracellular domain, 7 transmembrane domains, 3 intracellular loops, 3 extracellular loops and a carboxyl (C)-terminal intracellular domain. 2, 5 Most GPCRs comprise 300-500 amino acids, while some consist of more than 1000 amino acids. 2 GPCRs usually act as homodimers, heterodimers or oligomers. 4, 6, 7 Upon ligand binding, GPCRs undergo conformational changes that result in activation of the heterotrimeric G proteins ( Figure 1A ). 2, 8 In these processes, the third transmembrane domain rotates relative to the sixth domain. The activated G proteins then stimulate downstream signal cascades. Finally, GPCRs are C-terminally phosphorylated and undergo internalization and desensitization. The desensitization is mediated by β-arrestin and other proteins that bind to the C-terminal domain ( Figure 1A) . 34 The mutant receptor (red lines) lacked signal transduction activity; however, it can enhance the activity of the coexisting wild-type receptor GPCR that functions as a sensor for Ca 2+ , were observed in parathyroid tumours, CASR somatic mutations were not detected in these tissues.
| GPCR MUTATIONS AND DISORDERS
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Germline gain-of-function mutations in GPCR genes are also associated with endocrine disorders, albeit to a much lesser extent than loss-of-function mutations. To date, more than 100 germline activating mutations in GPCR genes have been reported (Table 1 and Figure 3 ). Of these, more than 70 were detected in CASR. [14] [15] [16] [17] [18] Patients with GPCR gain-of-function mutations manifest inappropriate hormone secretion or function that reflects excessive receptor activity ( Table 1 ). The phenotypes of these patients include both distinctive endocrine syndromes and nonspecific hormonal abnormalities. GPCR activating mutations cause endocrine disorders primarily in autosomal dominant or X-linked manners. Furthermore, gain-of-function mutations in GPCR genes can also appear as somatic mutations in endocrine tumour cells (Table 1) . These somatic mutations lead to hyperplasia of the glands and aberrant hormone secretion. 
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Gain-of-function mutations in CASR underlie a unique condition referred to as autosomal dominant hypocalcaemia (ADH). 15, 23 Patients with ADH exhibit hypocalcaemia, hyperphosphataemia and relative hypercalciuria, combined with low or normal parathyroid hormone though the underlying mechanism of GH oversecretion and tumourigenesis in these cases remains to be determined.
T A B L E 1 Examples of gain-of-function (GOF) mutations in GPCR genes leading to endocrine disorders
| RELATIVELY COMMON HORMONAL ABNORMALITIES CAUSED BY GERMLINE GPCR ACTIVATING MUTATIONS
GPCR gain-of-function mutations in the germline can also be associ- Similarly, germline gain-of-function mutations in TSHR encoding the thyroid-stimulating hormone receptor are known to cause hyperthyroidism. 28 Whereas these mutations usually lead to familial nonautoimmune hyperthyroidism or sporadic congenital nonautoimmune hyperthyroidism, they can occasionally underlie hyperthyroidism associated with low levels of thyroid antibodies. 28 This suggests that TSHR activating mutations may be present in some patients clinically diagnosed with Graves' disease. 28 Moreover, a homozygous missense mutation in MC2R (ACTHR) has been detected in a patient with ACTHindependent Cushing's syndrome.
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| ENDOCRINE TUMOURS CAUSED BY SOMATIC GPCR ACTIVATING MUTATIONS
Somatically acquired gain-of-function mutations in GPCR genes have been identified in endocrine tumours. In particular, somatic TSHR mutations are known as the major cause of autonomous thyroid adenomas. 13 Furthermore, TSHR mutations are also associated with the development of thyroid carcinoma. 1, 13 The mutation-positive lesions in the thyroid strongly express the sodium iodine symporter and thyroperoxidase, and are characterized by high radioiodine uptake and spontaneous thyroxine secretion. These lesions can cause hyperthyroidism in the mutation-positive patients.
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Likewise, a somatically acquired p.D578H mutation in LHCGR was
shown to underlie Leydig cell adenomas. [30] [31] [32] This mutation results in gonadotrophin-independent testosterone hypersecretion from the testis and thereby induces precocious puberty in boys. Moreover, the p.E308D mutation in GPR101 was identified in pituitary adenomas and predicted to cause GH oversecretion. 26 Notably, the same GPR101 mutation was also reported as a germline abnormality leading to X-LAG. 26 
F I G U R E 3
| NUCLEOTIDE ALTERATIONS LEADING TO GPCR GAIN-OF-FUNCTION
Gain-of-function of GPCRs results from various missense substitutions widely distributed in the coding regions (Table 1 and Figure 3 ). The N-terminal domain, the third intracellular loop and the sixth transmembrane domain appear to be hot spots for gain-of-function missense mutations (Figure 3) . 33 In addition, inframe deletions in CASR and TSHR, as well as frameshift mutations in CASR and PROKR2 have been documented to exert gain-of-function effects. 14, 17, 33, 34 Relatively large
N-and C-terminal domains of CASR likely provide hot spots for gain-offunction mutations (Figure 3). Chromosomal microduplications on Xq26
involving GPR101 are known as genetic causes of X-LAG. 25, 26 Most previously reported activating mutations in GPCR genes were specifically identified either in the germline or in somatic cells, although some mutations were found in both cell types (Table 1 ). It is possible that somatic mutations exert more severe effects than germline mutations. Indeed, Marx proposed that p.D578H in LHCGR, a mutation exclusively identified as somatic abnormalities, may cause early embryonic lethality.
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Germline activating mutations in GPCR genes are usually identified in a heterozygous state with the exception of mutations in AVPR2 and GPR101 on the X chromosome and specific mutations in CASR and MC2R
(ACTHR) that were identified in a homozygous state. 1, 16, 29 This suggests that most germline activating GPCR mutations on one allele are sufficient to cause clinically discernible abnormalities. Such mutations cause endocrine disorders primarily in an autosomal dominant manner. 
| INCREASED CONSTITUTIVE ACTIVITY OF MOST GPCR GAIN-OF-FUNCTION MUTANTS
Typically, pathogenic gain-of-function mutants of GPCRs present with increased constitutive activity ( Figure 1B) . 1, 3, 8 In vitro assays have demonstrated high basal activity of several missense mutations in the third intracellular loop or the sixth transmembrane domain, as well as an inframe deletion in the third intracellular loop of TSHR. 8, 33 Such mutations probably induce receptor isomerization from an inactive state to an active state even in the absence of the ligands 8 and thereby result in inappropriate hormone secretion.
Constitutively active GPCR mutants usually retain normal sensitivity and specificity to the ligands. However, in some cases, the maximum response of the mutants is higher or lower than that of the wild-type proteins. 5 Moreover, the expression levels of these mutant proteins can also be variable. In addition, GPCR mutations can alter the preference of the downstream signal cascades. 5 Thus, each GPCR gain-of-function mutant may have a unique functional property.
It is worth mentioning that increased basal activity of GPCRs is not necessarily pathogenic. Ligand-independent activation may be a fairly common feature of GPCRs, because several wild-type GPCRs in humans and other species show high basal activity without causing any phenotypic abnormalities. 8 It is possible that constitutive active mutants of GPCR are generated more frequently than presently expected, because such mutants are often recognized as misfolded proteins and are prevented from being expressed on the cell surface.
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| GPCR GAIN-OF-FUNCTION MECHANISMS OTHER THAN CONSTITUTIVE ACTIVATION
In some cases, GPCR gain-of-function mutants cause endocrine disorders through mechanisms other than increased constitutive activity ( Figure 1B) . First, the p.K183R and p.K183N mutants of TSHR exhibit hypersensitivity to human chorionic gonadotrophin (hCG), a hormone that only weakly stimulates the wild-type TSHR. 36, 37 Patients carrying these mutations show excessive thyroid hormone secretion in the presence of normal blood levels of hCG. Thus, the mutant receptors appear to have broader ligand specificity than the wild-type protein.
Second, the p.L125P mutant of CASR was shown to have increased sensitivity to its native ligand, Ca 2+ 18 In vitro assays demonstrated a significant left shift of the dose-response curve to Ca
2+
, in addition to slightly increased basal activity. 18 The mutation-positive patient exhibited severe hypocalcaemia that was consistent with hypersensitivity of the mutant receptor. Third, the p.R386P mutant of KISS1R retained normal basal activity and could normally respond to its ligand KISS1; however, the mutant receptor showed prolonged signal transduction after ligand stimulation. 27 Moreover, the mutant was located on the cell surface membrane for a longer period after ligand stimulation than the wild-type KISS1R. A female patient with the p.R386P mutation manifested central precocious puberty ascribable to excessive signal transduction of KISS1R. Thus, this mutant was predicted to exert gain-of-function effects through delayed internalization and desensitization. Similarly, defective desensitization of the p.278C mutant of MC2R (ACTHR) has been reported as the cause of ACTH-independent glucocorticoid oversecretion and adrenocortical hyperplasia.
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The abovementioned data suggest that gain-of-function mechanisms of GPCR mutants include constitutive activity, broad ligand specificity, high ligand sensitivity and delayed desensitization.
Moreover, other mechanisms, such as enhanced cell surface expression and increased sensitivity to the interacting proteins, may also result in excessive signal transduction of GPCR mutants. 
| A NOVEL MECHANISM FOR GPCR GAIN-OF-FUNCTION
Recently, we reported a unique GPCR gain-of-function mechanism underlying hormone overproduction ( Figure 1C) . 34 We identified a heterozygous frameshift mutation (p.C242fsX305) in PROKR2 in a girl with central precocious puberty. PROKR2 encodes a hypothalamic GPCR involved in gonadotrophin regulation. 10, 38 The p.C242fsX305 mutation was identified through systematic mutation screening of genes known to be involved in gonadotrophin secretion. and that GPCR heterodimers often have unique functional properties different from that of individual receptors. 6, 7 The phenotype of the mutation-positive patient was consistent with excessive gonadotrophin secretion due to gain-of-function of PROKR2. 10 These data challenge the classical view that GPCR gain-of-function mutations invariably encode receptor proteins with excessive signal transduction activity. Notably, however, the p.C242fsX305 mutation was shared by the patient's mother who experienced age-appropriate pubertal development. Thus, PROKR2 activating mutations appear to be associated with incomplete penetrance or variable expressivity.
As PROKR2 loss-of-function mutations were shown to have a wide phenotypic spectrum, 11, 40 clinical outcomes of PROKR2 abnormalities may be modified by other factors. Moreover, it remains possible that the p.C242fsX305 mutation is a functionally neutral variant.
Thus, the pathogenicity of this mutation needs to be confirmed by future studies.
Our findings of the naturally occurring PROKR2 mutation are con- is not readily achieved in patients with X-LAG due to GPR101 mutations. 26 Lastly, understanding of the molecular basis of each endocrine disorder may serve to develop new therapeutic options, as described below.
| MOLECULAR DIAGNOSIS OF PATIENTS WITH GPCR GAIN-OF-FUNCTION MUTATIONS
| FUTURE DIRECTIONS
The current understanding of pathogenic GPCR activating mutations is still fragmentary. Considering the large number of GPCR genes in the human genome, 1,2 several pathogenic GPCR mutations may remain undetermined. Systematic mutation screening of patients with various genetic disorders may identify such mutations. In addition, it remains to be clarified whether paradoxical gain-of-function phenomena caused by an inactive mutant are applicable to GPCRs other than
PROKR2.
Furthermore, the clinical outcomes of GPCR gain-of-function variants may not be limited to Mendelian disorders. It is possible that GPCR variants with excessive activity are associated with the risk of multifactorial conditions including obesity and metabolic disorders. Indeed, a rare polymorphism in ADRA2 encoding the α2A-adrenergic receptor was predicted to increase the risk of type 2 diabetes mellitus through excessive signal transduction. 42 Thus, there may be further GPCR activating variants involved in human health.
Attempts are being made to develop new pharmacological options for endocrine disorders resulting from GPCR activating mutations. The aim of current studies is to establish novel therapeutic strategies that directly correct the aberrant signal transduction caused by GPCR mutants. For example, calcilytic compounds (allosteric inhibitors of CASR)
were suggested as a novel therapeutic approach for ADH. 
